Receptor for Advanced Glycation End Product-Dependent Activation of p38 Mitogen-Activated Protein Kinase Contributes to Amyloid-β-Mediated Cortical Synaptic Dysfunction
Open Access
- 26 March 2008
- journal article
- Published by Society for Neuroscience in Journal of Neuroscience
- Vol. 28 (13) , 3521-3530
- https://doi.org/10.1523/jneurosci.0204-08.2008
Abstract
Soluble amyloid-β (Aβ) peptide is likely to play a key role during early stages of Alzheimer9s disease (AD) by perturbing synaptic function and cognitive processes. Receptor for advanced glycation end products (RAGE) has been identified as a receptor involved in Aβ-induced neuronal dysfunction. We investigated the role of neuronal RAGE in Aβ-induced synaptic dysfunction in the entorhinal cortex, an area of the brain important in memory processes that is affected early in AD. We found that soluble oligomeric Aβ peptide (Aβ42) blocked long-term potentiation (LTP), but did not affect long-term depression, paired-pulse facilitation, or basal synaptic transmission. In contrast, Aβ did not inhibit LTP in slices from RAGE-null mutant mice or in slices from wild-type mice treated with anti-RAGE IgG. Similarly, transgenic mice expressing a dominant-negative form of RAGE targeted to neurons showed normal LTP in the presence of Aβ, suggesting that neuronal RAGE functions as a signal transducer for Aβ-mediated LTP impairment. To investigate intracellular pathway transducing RAGE activation by Aβ, we used inhibitors of stress activated kinases. We found that inhibiting p38 mitogen-activated protein kinase (p38 MAPK), but not blocking c-Jun N-terminal kinase activation, was capable of maintaining LTP in Aβ-treated slices. Moreover, Aβ-mediated enhancement of p38 MAPK phosphorylation in cortical neurons was reduced by blocking antibodies to RAGE. Together, our results indicate that Aβ impairs LTP in the entorhinal cortex through neuronal RAGE-mediated activation of p38 MAPK.Keywords
This publication has 75 references indexed in Scilit:
- AMPAR Removal Underlies Aβ-Induced Synaptic Depression and Dendritic Spine LossNeuron, 2006
- Non‐fibrillar β‐amyloid abates spike‐timing‐dependent synaptic potentiation at excitatory synapses in layer 2/3 of the neocortex by targeting postsynaptic AMPA receptorsEuropean Journal of Neuroscience, 2006
- Amyloid-β Peptide Inhibits Activation of the Nitric Oxide/cGMP/cAMP-Responsive Element-Binding Protein Pathway during Hippocampal Synaptic PlasticityJournal of Neuroscience, 2005
- Natural oligomers of the amyloid-β protein specifically disrupt cognitive functionNature Neuroscience, 2004
- Amyloid β Prevents Activation of Calcium/Calmodulin-Dependent Protein Kinase II and AMPA Receptor Phosphorylation During Hippocampal Long-Term PotentiationJournal of Neurophysiology, 2004
- RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brainNature Medicine, 2003
- Alzheimer Amyloid β-Peptide Inhibits the Late Phase of Long-Term Potentiation through Calcineurin-Dependent Mechanisms in the Hippocampal Dentate GyrusNeurobiology of Learning and Memory, 2002
- Toxicity of various amyloid ? peptide species in cultured human blood-brain barrier endothelial cells: Increased toxicity of Dutch-type mutantJournal of Neuroscience Research, 2000
- Spatial learning deficit in mice expressing human 751-amino acid β-amyloid precursor proteinNeuroReport, 1996
- RAGE and amyloid-β peptide neurotoxicity in Alzheimer's diseaseNature, 1996